Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 1.00 |
| ▸ | NDUFS8 | O00217 | 5/20 | 1.00 |
| ▸ | COXFA4 | O00483 | 5/20 | 1.00 |
| ▸ | NDUFAB1 | O14561 | 5/20 | 1.00 |
| ▸ | NDUFA1 | O15239 | 5/20 | 1.00 |
| ▸ | NDUFS4 | O43181 | 5/20 | 1.00 |
| ▸ | NDUFB5 | O43674 | 5/20 | 1.00 |
| ▸ | NDUFB3 | O43676 | 5/20 | 1.00 |
| ▸ | NDUFC1 | O43677 | 5/20 | 1.00 |
| ▸ | NDUFA2 | O43678 | 5/20 | 1.00 |
| ▸ | NDUFS5 | O43920 | 5/20 | 1.00 |
| ▸ | NDUFS7 | O75251 | 5/20 | 1.00 |
| ▸ | NDUFS2 | O75306 | 5/20 | 1.00 |
| ▸ | NDUFS6 | O75380 | 5/20 | 1.00 |
| ▸ | NDUFB1 | O75438 | 5/20 | 1.00 |
| ▸ | NDUFS3 | O75489 | 5/20 | 1.00 |
| ▸ | NDUFB6 | O95139 | 5/20 | 1.00 |
| ▸ | NDUFA3 | O95167 | 5/20 | 1.00 |
| ▸ | NDUFB4 | O95168 | 5/20 | 1.00 |
| ▸ | NDUFB8 | O95169 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Auraptene SCHEMBL2535029 | 1.00 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| Umbelliprenin SCHEMBL28133292 | 0.99 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| Umbelliprenin SCHEMBL18265478 | 0.99 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| Umbelliprenin SCHEMBL26641528 | 0.99 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| SCHEMBL17898118 | 0.92 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| SCHEMBL17898120 | 0.92 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| SCHEMBL17898114 | 0.91 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| SCHEMBL17898115 | 0.91 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| SCHEMBL17898119 | 0.91 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 | |
| SCHEMBL17898117 | 0.91 | ALOX15 (1.00) | ALOX15NDUFS8COXFA4NDUFAB1NDUFA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3347486-A2 | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHODS OF TREATING ALZHEIMER'S DISEASE | The Trustees of Columbia University in the City of New York (US) | 2018-07-18 | — | — | EP | claimed |
| WO-2017044807-A2 | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHODS OF TREATING ALZHEIMER'S DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-03-16 | — | — | WO | claimed |
| US-20070293563-A1 | Novel Agents for Preventing and Treating Disorders Connected to Impaired Neurotransmission | DSM IP ASSETS B.V. (NL) | 2007-12-20 | — | — | US | claimed |
| EP-1802298-A2 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSMIP Assets B.V. (NL) | 2007-07-04 | — | — | EP | claimed |
| WO-2006042441-A2 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS B.V. (NL) | 2006-04-27 | — | — | WO | claimed |
| JP-63104973-A | — | — | None | — | — | JP | disclosed |
| WO-2024120329-A1 | METHOD FOR DIFFERENTIATING PLATELETS, CULTURE MEDIUM, AND USE | 苏州血霁生物科技有限公司 | 2024-06-13 | — | — | WO | disclosed |
| CN-118147070-A | Method for promoting in-vitro expansion of hematopoietic stem progenitor cells | 苏州血霁生物科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024108461-A1 | METHOD FOR PLATELET DIFFERENTIATION, CULTURE MEDIUM, AND USE THEREOF | 苏州血霁生物科技有限公司 | 2024-05-30 | — | — | WO | disclosed |
| US-11559512-B2 | Composition for prevention, alleviation, and/or treatment of heat illness | TOYO UNIVERSITY (JP) | 2023-01-24 | — | — | US | disclosed |
| US-20220395486-A1 | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHODS OF TREATING ALZHEIMER'S DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-12-15 | — | — | US | disclosed |
| US-11266626-B2 | Reduction of ER-MAM-localized APP-C99 and methods of treating alzheimer's disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-03-08 | — | — | US | disclosed |
| US-8044094-B2 | Agents for preventing and treating disorders connected to impaired neurotransmission | DSM IP ASSETS B.V. (NL) | 2011-10-25 | — | — | US | disclosed |
| CN-101703239-A | Novel agents for preventing and treating disorders connected to impaired neurotransmission | DSM IP ASSETS BV | 2010-05-12 | — | — | CN | disclosed |
| EP-1802298-B1 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS BV (NL) | 2008-12-31 | — | — | EP | disclosed |
| US-20070293563-A1 | Novel Agents for Preventing and Treating Disorders Connected to Impaired Neurotransmission | DSM IP ASSETS B.V. (NL) | 2007-12-20 | — | — | US | disclosed |
| CN-101043886-A | Novel agents for the prevention and treatment of disorders associated with impaired neurotransmission | DSM IP ASSETS BV (NL) | 2007-09-26 | — | — | CN | disclosed |
| EP-1802298-A2 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSMIP Assets B.V. (NL) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006042441-A2 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS B.V. (NL) | 2006-04-27 | — | — | WO | disclosed |
| JP-S63104973-A | COUMARIN DERIVATIVE | OTSUKA PHARMACEUT CO LTD | 1988-05-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559512-B2 | Composition for prevention, alleviation, and/or treatment of heat illness | TNF, HSF1, HSP90AA1 | ALOX15 96/4885NDUFS8 1512/4885COXFA4 515/4885 |
| US-20070293563-A1 | Novel Agents for Preventing and Treating Disorders Connected to Impaired Neurotransmission | CHRNA2, CHRM1, CHRM5 | ALOX15 1107/4885NDUFS8 649/4885COXFA4 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.